Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo
Nathan Kline Institute for Psychiatric Research · AstraZeneca (Sweden) · +1 more institution
Abstract
Neurofibrillary tangles composed of hyperphosphorylated, aggregated tau are a common pathological feature of tauopathies, including Alzheimer's disease. Abnormal phosphorylation of tau by kinases or phosphatases has been proposed as a pathogenic mechanism in tangle formation. To investigate whether kinase inhibition can reduce tauopathy and the degeneration associated with it in vivo, transgenic mice overexpressing mutant human tau were treated with the glycogen synthase kinase-3 (GSK-3) inhibitor lithium chloride. Treatment resulted in significant inhibition of GSK-3 activity. Lithium administration also resulted in significantly lower levels of phosphorylation at several epitopes of tau known to be…
Citation impact
- FWCI
- 24.45
- Percentile
- 100%
- References
- 46
Authors
17- WNWendy NobleCorresponding
Nathan Kline Institute for Psychiatric Research, AstraZeneca (Sweden), Mayo Clinic in Florida
- EPEmmanuel Planel
Nathan Kline Institute for Psychiatric Research, AstraZeneca (Sweden), Mayo Clinic in Florida
- CZCindy Zehr
Nathan Kline Institute for Psychiatric Research, AstraZeneca (Sweden), Mayo Clinic in Florida
- VOVicki Olm
Nathan Kline Institute for Psychiatric Research, AstraZeneca (Sweden), Mayo Clinic in Florida
- JLJordana L. Meyerson
Nathan Kline Institute for Psychiatric Research, AstraZeneca (Sweden), Mayo Clinic in Florida
Topics & keywords
- Tauopathy
- GSK-3
- Tangle
- Kinase
- Glycogen synthase
- Phosphorylation
- Lithium (medication)
- GSK3B
- Good health and well-being